The House has introduced H. Res. 928, a nonbinding resolution titled Affirming support for most-favored-Nation drug pricing for United States patients.
The measure cites studies showing the United States spends more per capita on prescription drugs than peer nations and references executive actions and presidential communications advocating lower prices. It states that U.S. pricing should be aligned with the lowest prices offered in other developed nations and that Medicare drug price negotiation should be expanded to promote price competition in the drug market.
As a nonbinding statement of policy, the resolution does not impose obligations or create enforcement mechanisms. Instead, it signals Congress’s policy direction and frames future legislative or regulatory proposals aimed at reducing patient costs and increasing access to prescription medications.
The resolution emphasizes that Americans should have access to high-quality, affordable prescription drugs and positions price alignment as a core objective for federal policy.
At a Glance
What It Does
The resolution declares that the United States should not charge more for the same prescription drugs than the lowest price offered in other developed nations. It also endorses expanding Medicare drug price negotiation and promoting price competition in the drug market.
Who It Affects
Directly relevant to federal policy and programs such as Medicare and Medicaid, private payers, and pharmaceutical manufacturers. It signals potential policy directions that could impact payers, providers, and patients.
Why It Matters
It frames a clear policy stance on drug pricing that could influence future legislation, regulatory actions, and budget deliberations, especially around drug affordability and the role of Medicare negotiations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
This is a nonbinding House resolution that takes a stance on prescription drug pricing rather than creating new rules. It highlights data showing higher U.S. drug costs relative to other nations and notes executive actions aimed at lowering prices.
The central idea is to align U.S. pricing with the lowest prices paid abroad for the same drugs and to bolster Medicare’s negotiating power while encouraging competition to reduce costs.
The Five Things You Need to Know
The resolution is nonbinding and serves as policy direction, not law.
It advocates aligning U.S. drug prices with the lowest prices in developed nations.
It supports expanding Medicare drug price negotiation to drive savings.
It promotes price competition within the U.S. pharmaceutical market.
It asserts that Americans should have access to affordable, high-quality prescription drugs.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings and purpose
The resolution opens with findings about the high level and growth of U.S. prescription drug spending, drawing on 2024 studies that show U.S. prices are substantially higher than those in peer countries. It cites polling on cost-related medication challenges and notes prior executive actions aimed at lowering prices. These preambular statements set the context and rationales for pursuing lower prices and greater negotiation power.
MFN pricing alignment and negotiation
The core policy directive is to support pricing the United States to match the lowest price offered in other developed nations. It also endorses expanding Medicare drug price negotiation and increasing price competition in the market, signaling potential pathways for future legislation or regulation.
Nonbinding policy statement
The measure is a resolution, not a statute. It expresses the House’s intent and policy preference but does not create enforceable obligations or direct funding. Its primary effect is to equip policymakers with a clear stance to inform forthcoming proposals.
Access and quality of care
The resolution closes by reiterating the goal of ensuring that all United States citizens have access to high-quality, affordable prescription drugs, framing affordability as a national objective.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries who may benefit from stronger price negotiation if implemented in future policies
- U.S. patients facing high out-of-pocket costs for prescriptions
- State Medicaid programs seeking potential savings from lower drug prices
- Private insurers and employer-sponsored plans that could see reduced drug costs
- Policy analysts and health economists seeking clearer directional signals for reform
Who Bears the Cost
- Pharmaceutical manufacturers that could face pricing pressures if MFN pricing or expanded negotiations influence pricing dynamics
- Brand-name and specialty drug companies projected to experience tighter margins under stronger price discipline
- Some private payers may incur transitional costs adjusting to new negotiation frameworks
- Government programs funding or evaluating future pricing reforms could bear administrative or regulatory costs
Key Issues
The Core Tension
Balancing affordability with innovation and supply: can aggressive MFN-based pricing and expanded Medicare negotiation reduce costs without dampening drug development or limiting patient access to new therapies?
The resolution articulates a policy preference for MFN-based pricing and expanded Medicare negotiation, but it leaves unresolved questions about how such alignment would be operationalized in law, regulation, or payer contracts. Key tensions include how to define the “lowest price” across developed nations, how to handle differences in draft pricing for biologics versus small-molecule drugs, and how to avoid unintended supply or access disruptions if prices are compressed too aggressively.
The measure does not specify funding, enforcement, or oversight mechanisms, so any real-world impact would depend on subsequent legislation and regulatory action. It also assumes that lower negotiated prices will translate into broader affordability for patients, an assumption that may hinge on formulary decisions, rebates, and market competition.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.